Top

Published in:

01-05-2020 | Itraconazole | Original Article

Therapeutic effect of an anti-human-TNF-alpha antibody and itraconazole on feline infectious peritonitis

Authors: Tomoyoshi Doki, Masahiro Toda, Nobuhisa Hasegawa, Tsutomu Hohdatsu, Tomomi Takano

Published in: Archives of Virology | Issue 5/2020

Abstract

Feline infectious peritonitis (FIP) is a fatal disease in wild and domestic cat species. Although several drugs are expected to be useful as treatments for FIP, no drugs are available in clinical practice. In this study, we evaluated the therapeutic effect of combined use of adalimumab (an anti-human-TNF-alpha monoclonal antibody, ADA) and itraconazole (ICZ), which are presently available to veterinarians. The neutralizing activity of ADA against fTNF-alpha-induced cytotoxicity was measured in WEHI-164 cells. Ten specific pathogen-free (SPF) cats were inoculated intraperitoneally with type I FIPV KU-2. To the cats that developed FIP, ADA (10 mg/animal) was administered twice between day 0 and day 4 after the start of treatment. ICZ (50 mg/head, SID) was orally administered daily from day 0 after the start of treatment. ADA demonstrated dose-dependent neutralizing activity against rfTNF-alpha. In an animal experiment, 2 of 3 cats showed improvements in FIP clinical symptoms and blood chemistry test results, an increase in the peripheral blood lymphocyte count, and a decrease in the plasma alpha 1-AGP level were observed after the beginning of treatment. One of the cats failed to respond to treatment and was euthanized, although the viral gene level in ascites temporarily decreased after the start of treatment. ADA was found to have neutralizing activity against rfTNF-alpha. The combined use of ADA and ICZ showed a therapeutic effect for experimentally induced FIP. We consider these drugs to be a treatment option until effective anti-FIPV drugs become available.

Pedersen NC (2014) An update on feline infectious peritonitis: diagnostics and therapeutics. Vet J 201:133–141. https://doi.org/10.1016/j.tvjl.2014.04.016CrossRefPubMed

Tekes G, Thiel HJ (2016) Feline coronaviruses: pathogenesis of feline infectious peritonitis. In: Ziebuhr J (ed) Advances in virus research, vol. 96, Academic Press, pp 193–218

Jaimes JA, Whittaker GR (2018) Feline coronavirus: insights into viral pathogenesis based on the spike protein structure and function. Virology 517:108–121. https://doi.org/10.1016/j.virol.2017.12.027CrossRefPubMed

Decaro N, Mari V, Campolo M et al (2009) Recombinant canine coronaviruses related to transmissible gastroenteritis virus of swine are circulating in dogs. J Virol 83:1532–1537. https://doi.org/10.1128/jvi.01937-08CrossRefPubMed

Herrewegh AA, Smeenk I, Horzinek MC et al (1998) Feline coronavirus type II strains 79-1683 and 79-1146 originate from a double recombination between feline coronavirus type I and canine coronavirus. J Virol 72:4508–4514CrossRefPubMed

Terada Y, Shiozaki Y, Shimoda H et al (2012) Feline infectious peritonitis virus with a large deletion in the 59-terminal region of the spike gene retains its virulence for cats. J Gen Virol 93:1930–1934. https://doi.org/10.1099/vir.0.043992-0CrossRefPubMed

Addie DD, Schaap IAT, Nicolson L, Jarrett O (2003) Persistence and transmission of natural type I feline coronavirus infection. J Gen Virol 84:2735–2744. https://doi.org/10.1099/vir.0.19129-0CrossRefPubMed

Kummrow M, Meli ML, Haessig M et al (2005) Feline coronavirus serotypes 1 and 2: seroprevalence and association with disease in Switzerland. Clin Diagn Lab Immunol 12:1209–1215. https://doi.org/10.1128/CDLI.12.10.1209-1215.2005CrossRefPubMed

Hohdatsu T, Okada S, Ishizuka Y et al (1992) The prevalence of types I and II feline coronavirus infections in cats. J Vet Med Sci 54:557–562. https://doi.org/10.1292/jvms.54.557CrossRefPubMed

10.

Takano T, Hohdatsu T, Hashida Y et al (2007) A “possible” involvement of TNF-alpha in apoptosis induction in peripheral blood lymphocytes of cats with feline infectious peritonitis. Vet Microbiol 119:121–131. https://doi.org/10.1016/j.vetmic.2006.08.033CrossRefPubMed

11.

Takano T, Hohdatsu T, Toda A et al (2007) TNF-alpha, produced by feline infectious peritonitis virus (FIPV)-infected macrophages, upregulates expression of type II FIPV receptor feline aminopeptidase N in feline macrophages. Virology 364:64–72. https://doi.org/10.1016/j.virol.2007.02.006CrossRefPubMed

12.

Takano T, Azuma N, Satoh M et al (2009) Neutrophil survival factors (TNF-alpha, GM-CSF, and G-CSF) produced by macrophages in cats infected with feline infectious peritonitis virus contribute to the pathogenesis of granulomatous lesions. Arch Virol 154:775–781. https://doi.org/10.1007/s00705-009-0371-3CrossRefPubMed

13.

Doki T, Takano T, Nishiyama Y et al (2013) Generation, characterization and therapeutic potential of anti-feline TNF-alpha MAbs for feline infectious peritonitis. Res Vet Sci 95:1248–1254. https://doi.org/10.1016/j.rvsc.2013.09.005CrossRefPubMed

14.

Doki T, Takano T, Kawagoe K et al (2016) Therapeutic effect of anti-feline TNF-alpha monoclonal antibody for feline infectious peritonitis. Res Vet Sci 104:17–23. https://doi.org/10.1016/j.rvsc.2015.11.005CrossRefPubMed

15.

Tracey D, Klareskog L, Sasso EH et al (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117:244–279CrossRefPubMed

16.

Kim Y, Lovell S, Tiew K-C et al (2012) Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J Virol 86:11754–11762. https://doi.org/10.1128/JVI.01348-12CrossRefPubMed

17.

Kim Y, Liu H, Galasiti Kankanamalage AC et al (2016) Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor. PLoS Pathog 12:e1005531. https://doi.org/10.1371/journal.ppat.1005531CrossRefPubMed

18.

Murphy BG, Perron M, Murakami E et al (2018) The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies. Vet Microbiol 219:226–233. https://doi.org/10.1016/j.vetmic.2018.04.026CrossRefPubMed

19.

Pedersen NC, Kim Y, Liu H et al (2018) Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis. J Feline Med Surg 20:378–392. https://doi.org/10.1177/1098612X17729626CrossRefPubMed

20.

Pedersen NC, Perron M, Bannasch M et al (2019) Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. J Feline Med Surg 21:271–281. https://doi.org/10.1177/1098612X19825701CrossRefPubMed

21.

Takano T, Akiyama M, Doki T, Hohdatsu T (2019) Antiviral activity of itraconazole against type I feline coronavirus infection. Vet Res 50:5. https://doi.org/10.1186/s13567-019-0625-3CrossRefPubMed

22.

Takano T, Endoh M, Fukatsu H et al (2017) The cholesterol transport inhibitor U18666A inhibits type I feline coronavirus infection. Antivir Res 145:96–102. https://doi.org/10.1016/j.antiviral.2017.07.022CrossRefPubMed

23.

Takano T, Wakayama Y, Doki T (2019) Endocytic pathway of feline coronavirus for cell entry: differences in serotype-dependent viral entry pathway. Pathogens 8:300. https://doi.org/10.3390/pathogens8040300CrossRef

24.

Koga L, Kobayashi Y, Yazawa M et al (2002) Nucleotide sequence and expression of the feline vascular endothelial growth factor. J Vet Med Sci 64:453–456. https://doi.org/10.1292/jvms.64.453CrossRefPubMed

25.

Fronhoffs S, Totzke G, Stier S et al (2002) A method for the rapid construction of cRNA standard curves in quantitative real-time reverse transcription polymerase chain reaction. Mol Cell Probes 16:99–110. https://doi.org/10.1006/mcpr.2002.0405CrossRefPubMed

26.

Aguirre A, Escobar A, Ferreira V et al (2003) An anti-human recombinant tumor necrosis factor alpha (TNFα) monoclonal antibody recognizes an epitope in feline TNFα. Vet Res 34:177–184. https://doi.org/10.1051/vetres:2002064CrossRefPubMed

27.

Hu S, Liang S, Guo H et al (2013) Comparison of the inhibition mechanisms of Adalimumab and Infliximab in treating tumor necrosis factor α-associated diseases from a molecular view. J Biol Chem 288:27059–27067. https://doi.org/10.1074/jbc.M113.491530CrossRefPubMed

28.

Takano T, Ohyama T, Kokumoto A et al (2011) Vascular endothelial growth factor (VEGF), produced by feline infectious peritonitis (FIP) virus-infected monocytes and macrophages, induces vascular permeability and effusion in cats with FIP. Virus Res 158:161–168. https://doi.org/10.1016/j.virusres.2011.03.027CrossRefPubMed

29.

García Rodrǐguez LA, Duque A, Castellsague J et al (1999) A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol 48:847–852. https://doi.org/10.1046/j.1365-2125.1999.00095.xCrossRefPubMed

30.

Kao WY, Su CW, Huang YS et al (2014) Risk of oral antifungal agent-induced liver injury in Taiwanese. Br J Clin Pharmacol 77:180–189. https://doi.org/10.1111/bcp.12178CrossRefPubMed

31.

Susan M, Grant SPC (1989) Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 37:310–344CrossRef

32.

Khoza S, Moyo I, Ncube D (2017) Comparative hepatotoxicity of fluconazole, ketoconazole, itraconazole, terbinafine, and griseofulvin in rats. J Toxicol. https://doi.org/10.1155/2017/6746989CrossRefPubMed

Title: Therapeutic effect of an anti-human-TNF-alpha antibody and itraconazole on feline infectious peritonitis
Authors: Tomoyoshi Doki
Masahiro Toda
Nobuhisa Hasegawa
Tsutomu Hohdatsu
Tomomi Takano
Publication date: 01-05-2020
Publisher: Springer Vienna
Keywords: Itraconazole
Adalimumab
Peritonitis
Ascites
Published in: Archives of Virology / Issue 5/2020
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-020-04605-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Therapeutic effect of an anti-human-TNF-alpha antibody and itraconazole on feline infectious peritonitis

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2020

Seroprevalence and factors associated with hepatitis B virus infection in blood donors in Ethiopia: a systematic review and meta-analysis

Higher virulence of swine H1N2 influenza viruses containing avian-origin HA and 2009 pandemic PA and NP in pigs and mice

Molecular epidemiology of respiratory syncytial virus for 28 consecutive seasons (1990-2018) and genetic variability of the duplication region in the G gene of genotypes ON1 and BA in South Korea

Development and optimization of a DNA-based reverse genetics systems for epizootic hemorrhagic disease virus

The nucleic acid positive rate and genotype distribution of human cytomegalovirus in human milk banks in China

A novel narnavirus from the plant-pathogenic fungus Magnaporthe oryzae

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page